ArticleBritish journal of cancer2010
Flexible modeling improves assessment of prognostic value of C-reactive protein in advanced non-small cell lung cancer.
Article in British journal of cancer, 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 4 syntheses or guidelines pooled it, 47 citations in OpenAlex.
- Utility of High-Sensitivity Modified Glasgow Prognostic Score in Cancer Prognosis: A Systemic Review and Meta-Analysis.International journal of molecular sciences · 2023Pooled it
- Prognostic value of C-reactive protein levels in patients with bone neoplasms: A meta-analysis.PloS one · 2018Pooled it
- C-reactive protein as a prognostic factor for human osteosarcoma: a meta-analysis and literature review.PloS one · 2014Pooled it
- Pooled it
- Review of Existing Approaches and Potential Role of Pharmacometrics in the Interpretation of Prognostic Circulating Serum Biomarkers in Advanced NSCLC.Clinical and translational science · 2026Review
- High level of C-reactive protein as a predictive factor for immune-related adverse events of immune checkpoint inhibitors in non-small cell lung cancer: a retrospective study.Journal of thoracic disease · 2023Article
- Flexible extension of the accelerated failure time model to account for nonlinear and time-dependent effects of covariates on the hazard.Statistical methods in medical research · 2021Article
- High serum C-reactive protein levels predict survival in patients with treated advanced lung adenocarcinoma.Journal of thoracic disease · 2021Article
- Observational
- A Nomogram based on Inflammatory Factors C-Reactive Protein and Fibrinogen to Predict the Prognostic Value in Patients with Resected Non-Small Cell Lung Cancer.Journal of Cancer · 2017Article
- Comparison of the Glasgow Prognostic Score (GPS) and the modified Glasgow Prognostic Score (mGPS) in evaluating the prognosis of patients with operable and inoperable non-small cell lung cancer.Journal of cancer research and clinical oncology · 2016Article
- Simple and Objective Prediction of Survival in Patients with Lung Cancer: Staging the Host Systemic Inflammatory Response.Lung cancer international · 2014Article
- Validation of the prognostic relevance of plasma C-reactive protein levels in soft-tissue sarcoma patients.British journal of cancer · 2013Article
- Montreal prognostic score: estimating survival of patients with non-small cell lung cancer using clinical biomarkers.British journal of cancer · 2013Article
- Elevated serum C-reactive protein as a prognostic marker in small cell lung cancer.Yonsei medical journal · 2012Article
- C-reactive protein concentration is associated with prognosis in patients suffering from peritoneal carcinomatosis of colorectal origin.International journal of colorectal disease · 2011Article
- Non-malignant drivers of elevated C-reactive protein levels differ in patients with and without a history of cancer.Molecular diagnosis & therapy · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 2 institutions in 1 country.
Funding
Abstract
backgroundC-reactive protein (CRP) is gaining credibility as a prognostic factor in different cancers. Cox's proportional hazard (PH) model is usually used to assess prognostic factors. However, this model imposes a priori assumptions, which are rarely tested, that (1) the hazard ratio associated with each prognostic factor remains constant across the follow-up (PH assumption) and (2) the relationship between a continuous predictor and the logarithm of the mortality hazard is linear (linearity assumption).
methodsWe tested these two assumptions of the Cox's PH model for CRP, using a flexible statistical model, while adjusting for other known prognostic factors, in a cohort of 269 patients newly diagnosed with non-small cell lung cancer (NSCLC).
resultsIn the Cox's PH model, high CRP increased the risk of death (HR=1.11 per each doubling of CRP value, 95% CI: 1.03-1.20, P=0.008). However, both the PH assumption (P=0.033) and the linearity assumption (P=0.015) were rejected for CRP, measured at the initiation of chemotherapy, which kept its prognostic value for approximately 18 months.
conclusionOur analysis shows that flexible modeling provides new insights regarding the value of CRP as a prognostic factor in NSCLC and that Cox's PH model underestimates early risks associated with high CRP.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.